Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation

Maroof Hasan, Charles S. Fermaintt, Ningguo Gao, Tomomi Sakai, Takuya Miyazaki, Sixin Jiang, Quan Zhen Li, John P. Atkinson, Herbert C. Morse, Mark A. Lehrman, Nan Yan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

TREX1 is an endoplasmic reticulum (ER)-associated negative regulator of innate immunity. TREX1 mutations are associated with autoimmune and autoinflammatory diseases. Biallelic mutations abrogating DNase activity cause autoimmunity by allowing immunogenic self-DNA to accumulate, but it is unknown how dominant frameshift (fs) mutations that encode DNase-active but mislocalized proteins cause disease. We found that the TREX1 C terminus suppressed immune activation by interacting with the ER oligosaccharyltransferase (OST) complex and stabilizing its catalytic integrity. C-terminal truncation of TREX1 by fs mutations dysregulated the OST complex, leading to free glycan release from dolichol carriers, as well as immune activation and autoantibody production. A connection between OST dysregulation and immune disorders was demonstrated in Trex1<sup>-/-</sup> mice, TREX1-V235fs patient lymphoblasts, and TREX1-V235fs knock-in mice. Inhibiting OST with aclacinomycin corrects the glycan and immune defects associated with Trex1 deficiency or fs mutation. This function of the TREX1 C terminus suggests a potential therapeutic option for TREX1-fs mutant-associated diseases.

Original languageEnglish (US)
Article number3143
Pages (from-to)463-474
Number of pages12
JournalImmunity
Volume43
Issue number3
DOIs
StatePublished - Sep 15 2015

Fingerprint

Frameshift Mutation
Deoxyribonucleases
Endoplasmic Reticulum
Polysaccharides
Dolichol
Mutation
Immune System Diseases
Autoimmunity
Innate Immunity
Autoantibodies
Autoimmune Diseases
dolichyl-diphosphooligosaccharide - protein glycotransferase
DNA
Proteins
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation. / Hasan, Maroof; Fermaintt, Charles S.; Gao, Ningguo; Sakai, Tomomi; Miyazaki, Takuya; Jiang, Sixin; Li, Quan Zhen; Atkinson, John P.; Morse, Herbert C.; Lehrman, Mark A.; Yan, Nan.

In: Immunity, Vol. 43, No. 3, 3143, 15.09.2015, p. 463-474.

Research output: Contribution to journalArticle

Hasan, Maroof ; Fermaintt, Charles S. ; Gao, Ningguo ; Sakai, Tomomi ; Miyazaki, Takuya ; Jiang, Sixin ; Li, Quan Zhen ; Atkinson, John P. ; Morse, Herbert C. ; Lehrman, Mark A. ; Yan, Nan. / Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation. In: Immunity. 2015 ; Vol. 43, No. 3. pp. 463-474.
@article{cf94d78066094fdcb726731a880faa32,
title = "Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation",
abstract = "TREX1 is an endoplasmic reticulum (ER)-associated negative regulator of innate immunity. TREX1 mutations are associated with autoimmune and autoinflammatory diseases. Biallelic mutations abrogating DNase activity cause autoimmunity by allowing immunogenic self-DNA to accumulate, but it is unknown how dominant frameshift (fs) mutations that encode DNase-active but mislocalized proteins cause disease. We found that the TREX1 C terminus suppressed immune activation by interacting with the ER oligosaccharyltransferase (OST) complex and stabilizing its catalytic integrity. C-terminal truncation of TREX1 by fs mutations dysregulated the OST complex, leading to free glycan release from dolichol carriers, as well as immune activation and autoantibody production. A connection between OST dysregulation and immune disorders was demonstrated in Trex1-/- mice, TREX1-V235fs patient lymphoblasts, and TREX1-V235fs knock-in mice. Inhibiting OST with aclacinomycin corrects the glycan and immune defects associated with Trex1 deficiency or fs mutation. This function of the TREX1 C terminus suggests a potential therapeutic option for TREX1-fs mutant-associated diseases.",
author = "Maroof Hasan and Fermaintt, {Charles S.} and Ningguo Gao and Tomomi Sakai and Takuya Miyazaki and Sixin Jiang and Li, {Quan Zhen} and Atkinson, {John P.} and Morse, {Herbert C.} and Lehrman, {Mark A.} and Nan Yan",
year = "2015",
month = "9",
day = "15",
doi = "10.1016/j.immuni.2015.07.022",
language = "English (US)",
volume = "43",
pages = "463--474",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation

AU - Hasan, Maroof

AU - Fermaintt, Charles S.

AU - Gao, Ningguo

AU - Sakai, Tomomi

AU - Miyazaki, Takuya

AU - Jiang, Sixin

AU - Li, Quan Zhen

AU - Atkinson, John P.

AU - Morse, Herbert C.

AU - Lehrman, Mark A.

AU - Yan, Nan

PY - 2015/9/15

Y1 - 2015/9/15

N2 - TREX1 is an endoplasmic reticulum (ER)-associated negative regulator of innate immunity. TREX1 mutations are associated with autoimmune and autoinflammatory diseases. Biallelic mutations abrogating DNase activity cause autoimmunity by allowing immunogenic self-DNA to accumulate, but it is unknown how dominant frameshift (fs) mutations that encode DNase-active but mislocalized proteins cause disease. We found that the TREX1 C terminus suppressed immune activation by interacting with the ER oligosaccharyltransferase (OST) complex and stabilizing its catalytic integrity. C-terminal truncation of TREX1 by fs mutations dysregulated the OST complex, leading to free glycan release from dolichol carriers, as well as immune activation and autoantibody production. A connection between OST dysregulation and immune disorders was demonstrated in Trex1-/- mice, TREX1-V235fs patient lymphoblasts, and TREX1-V235fs knock-in mice. Inhibiting OST with aclacinomycin corrects the glycan and immune defects associated with Trex1 deficiency or fs mutation. This function of the TREX1 C terminus suggests a potential therapeutic option for TREX1-fs mutant-associated diseases.

AB - TREX1 is an endoplasmic reticulum (ER)-associated negative regulator of innate immunity. TREX1 mutations are associated with autoimmune and autoinflammatory diseases. Biallelic mutations abrogating DNase activity cause autoimmunity by allowing immunogenic self-DNA to accumulate, but it is unknown how dominant frameshift (fs) mutations that encode DNase-active but mislocalized proteins cause disease. We found that the TREX1 C terminus suppressed immune activation by interacting with the ER oligosaccharyltransferase (OST) complex and stabilizing its catalytic integrity. C-terminal truncation of TREX1 by fs mutations dysregulated the OST complex, leading to free glycan release from dolichol carriers, as well as immune activation and autoantibody production. A connection between OST dysregulation and immune disorders was demonstrated in Trex1-/- mice, TREX1-V235fs patient lymphoblasts, and TREX1-V235fs knock-in mice. Inhibiting OST with aclacinomycin corrects the glycan and immune defects associated with Trex1 deficiency or fs mutation. This function of the TREX1 C terminus suggests a potential therapeutic option for TREX1-fs mutant-associated diseases.

UR - http://www.scopus.com/inward/record.url?scp=84941628442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941628442&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2015.07.022

DO - 10.1016/j.immuni.2015.07.022

M3 - Article

C2 - 26320659

AN - SCOPUS:84941628442

VL - 43

SP - 463

EP - 474

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 3

M1 - 3143

ER -